Pulmonary Neoplastic Disease Flashcards

1
Q

pulmonary nodule

A

-≤ 3 cm isolated, rounded opacity on cxr
-Outlined by normal lung
-Not associated with infiltrate, atelectasis, or adenopathy
-Most asymptomatic unexpected finding on cxr
-Most benign nodules are infectious granulomas
-Importance: carries a significant risk of malignancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what do we do about a pulmonary nodule

A

-Identify and resect malignant tumors in pts who stand to benefit from resection
-Avoid invasive procedures in benign disease
-Identify nodules with high probability of malignancy to warrant bx or resection
-Identify those with low probability of malignancy to justify observation
-CT is indicated in any suspicious solitary pulmonary nodule!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

lung cancer screening

A

-USPSTF recommends low-dose computed tomography (LDCT)*** in adults aged 50-80 years with 20 pack-year smoking hx and currently smoke or quit within past 15 years
-criteria expanded eligible population from 8-6 mil and is associated with increased overall proportion of women, racial and ethnic minority groups, and individuals with lower socioeconomic status who are eligible for screening
-Screening should be d/c if no smoking for 15 years or develop a health problem that substantially limits life expectancy or ability or willingness to have curative lung surgery
-Result- now detecting large numbers of lung nodules (majority benign)
-Estimated 237,000 people in the U.S. will be diagnosed with lung cancer this year.
-only 5.8% of eligible Americans have been screened
-many incidental nodules are found -> from other CT scans

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

lung cancer screening- requirements and benefits

A

-USPSTF recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years.
-Change in recent criteria expanded eligible population from 8 million to 16 million and is associated with an increased overall proportion of women, racial and ethnic minority groups, and individuals with lower socioeconomic status who are eligible for lung cancer screening.
-Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have a curative lung surgery.
-As a result, we are now detecting large numbers of lung nodules
-From a 2015 article there were 4.8 million CT scans performed in the US.
-1.57 million patients were found to have a lung nodule (125,000 from lung cancer screening)
-The overwhelming majority are benign nodules
-115,000 new cases of lung cancer each year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

how to evaluate nodule: age, smoker, prior malignancy

A

-Age:
-Malignant nodules are rare < 30 yo
-Likelihood of malignancy increases with age
-Smokers- Likelihood increases with number of cigarettes/day
-Prior malignancy:
-Higher likelihood of having a malignant solitary nodule

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

doubling time

A

-important marker for malignancy
-Rapid progression (doubling time less than 30 days) suggests infection
-Long term stability (doubling time over 500 days) suggests benignity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

radiographic features

A

-size
-calcifications
-borders

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

size of nodule

A

-Size is correlated with malignancy:
-A recent study of solitary nodules identified by CT scan:
-1% malignancy rate in those measuring 2–5 mm
-24% in 6–10 mm
-33% in 11–20 mm
-80% in 21–45 mm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

borders of nodule

A

-Benign process:
-Smooth, well-defined edge

-Malignancy:
-Ill-defined margins or lobular appearance
-Spiculated (jagged) margins and a peripheral halo -> Highly associated with malignancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

nodule: calcifications

A

-Benign lesions: Dense calcification
-Malignant lesions: Sparser calcification

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

nodule: cavitary

A

-infection vs malignant
-usually more infection but can be malignant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

diff dx of nodule

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

nodule tx: Low probability of malignancy (<5%)

A

-Watchful waiting:
-Age under 30
-Characteristic pattern of benign calcification

-Management:
-Serial CT scans at intervals that would identify growth that would suggest malignancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

nodule tx: high probability (>60%) of malignancy

A

-Directly to resection if no contraindications
-large and ugly looking nodules
-dont even need to bx sometimes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

nodule tx: intermediate probability of malignancy (5-60%)

A

-remains controversial
-Bx: transthoracic needle aspiration (TTNA) or bronchoscopy
-Pet Scan- look at metabolic activity not necessarily cancer -> cancer, infection, inflammation can light up
-Sputum cytology: highly specific but useless unless central lesion (not really used)
-Video-assisted thoracoscopic surgery (VATS) offers a more aggressive approach to dx -> high risk pts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

fleischner society risk scale: solid nodules

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

fleischner society risk scale: subsolid nodule

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

carcinoid tumors

A

-slow growing
-usually dont metastases
-doesnt act typical
-Low grade malignant neoplasms -> bronchial carcinoid tumors grow slowly and rarely metastasize
-Men=women
-Most patients usually < 60 yo

-Location:
-Central* bronchi -> Pedunculated or sessile growths
-usually in the larger airways

-Peripherally located:
-Present as asymptomatic solitary pulmonary nodules
-Rare

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

carcinoid tumors: S&S

A

-symptomatic bc in the airway
-Hemoptysis
-Cough
-Focal wheezing
-Recurrent pneumonia
-Carcinoid syndrome (flushing, diarrhea, wheezing, hypotension) is rare

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

carcinoid tumor dx

A

-Bronchoscopy: Pink or purple tumor in a central airway
-CT scanning: Localize the lesion and follow growth over time
-Octreotide scintigraphy, Dotatate PET/CT*: Localization of metastatic tumors (normal PET scan doesnt really show)
-neuroendocrine tumor
-Complications- Bleeding and airway obstruction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

carcinoid tumor tx

A

-Surgical excision
-Bronchoscopic removal if entirely endoluminal and poor surgical candidate
-Prognosis is generally favorable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

bronchogenic carcinoma

A

-this is the lung cancer you mostly think/worry about
-Leading cause of cancer deaths in men and women
-More Americans now die of lung cancer than of colorectal, breast, and prostate cancers combined
-Cigarette smoking causes > 85% of cases of lung ca
-Mean age at diagnosis 70: Unusual under the age 40
-decline in mortality- early detection!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

bronchogenic carcinoma risk factors

A

-Tobacco smoke*
-Radon gas
-Asbestos
-Metals
-Industrial carcinogens
-Familial predisposition
-Medical conditions
-Previous primary lung cancer

24
Q

bronchogenic carcinoma: 4 histologic types

A

-Account for majority of cases of primary lung cancer
-1. Squamous cell carcinoma (20%)
-2. Adenocarcinoma (38%) -> Bronchoalveolar cell carcinoma (2%)
-3. Large cell carcinoma (5%)
-4 .Small cell carcinoma (13%)- much more aggressive, staged differently (limited vs advanced)
-For staging known as small cell lung ca (SCLC) and non small cell lung ca (NSCLC)
-large cell can be cured surgically, not small cell

25
Q

lung cancer separated into

A

SCLC and NSCLC

26
Q

bronchogenic carcinoma: SCLC and NSCLC

A

-Reflects different natural histories and different treatment

-SCLC:
-Prone to early hematogenous spread
-Rarely amenable to surgical resection
-Very aggressive course with median survival (untreated) of 6–18 weeks

-NSCLC:
-Spreads more slowly
-May be cured in early stages following resection
-Respond similarly to chemotherapy
-can be cured with early surgery
-this is the one that benefits from early detection

27
Q

bronchogenic carcinoma: squamous cell carcinoma

A

-Arises from bronchial epithelium, typically as a CENTRALLY LOCATED, INTRALUMINAL sessile or polypoid mass
-More likely to present with hemoptysis
-More frequently diagnosed by sputum cytology- this is the only one really
-Spreads locally

28
Q

bronchogenic carcinoma: adenocarcinoma

A

-MC type*
-Arises from mucous glands
-Usually presents as PERIPHERAL nodules or masses
-Found in nonsmokers
-Bronchoalveolar cell carcinoma:
-Epithelial cell within or distal to the terminal bronchioles
-Spreads intra-alveolarly
-May present as an infiltrate or as single or multiple pulmonary nodules
-can look like pneumonia

29
Q

bronchogenic carcinoma: large cell carcinoma

A

-heterogeneous group of relatively undifferentiated tumors that share large cells and do not fit into other categories
-Typically have rapid doubling times and an aggressive clinical course
-They present as CENTRAL OR PERIPHERAL masses
-non small cell carcinomas

30
Q

bronchogenic carcinoma: small cell carcinoma

A

-Bronchial origin that typically begins centrally
-mediastinal adenopathy can happen
-Infiltrating submucosally causing narrowing or obstruction of the bronchus without a discrete luminal mass
-Hard to get bx because submucosal
-Metastasizes early and is aggressive

31
Q

clinical picture

A

-Type and location of the primary tumor
-Extent of local spread
-Presence of distant metastases
-Paraneoplastic syndromes

32
Q

paraneoplastic syndromes

A

-when tumor secretes something that causes other systemic findings
-almost all are small cell-> bc they are neuroendocrine tumors
-squamous cell- hypercalcemia (this is an exception to SCLC)*

33
Q

lung cancer symptoms

A

-mostly asymptomatic
-symptoms usually only in advanced
-cough, wt loss, dyspnea- MC

34
Q

lung cancer complications

A

-can be any cancer

35
Q

superior vena cava syndrome

A

-tumor obstructing/invading SVC
-facial edema and plethora
-venous distension distal to obstruction
-AMS, headache

36
Q

pancoasts tumor

A

-tumor of the lung apex
-causes horners syndrome and shoulder pain
-affects brachial plexus and cervcial sympathetic nerve

-Horner’s syndrome:
-unilateral
-problem with sympathetic nerve supple to one side of face
-miosis- constriction
-ptosis- droopy eye
-anhidrosis- failure to sweat

37
Q

metastases

A

-distant metastases:
-liver
-brain metastases (10%)

38
Q

work up: bx

A

-Dx: tissue or sputum/fluid cytology:
-Thoracentesis
-FNA: palpable supraclavicular or cervical nodes
-Bronchoscopy (10-90% yield)/EBUS
-Transthoracic needle bx with CT guidance
-Video assisted thoracoscopic surgery (VATS) if above fails or open thoracotomy - used in hard spots to reach or emphysema, or if sending straight to surgery without bx
-Mediastinoscopy

-Tumor markers: PDL1, ALK gene, EGFR gene -> in complement to bx

39
Q

staging work up (after confirmation of malignancy)

A

-ALL PATIENTS:
-Thorough history
-CBC
-Electrolytes, calcium
-Albumin, LFTs
-Renal function

-Additional tests based on previous findings for staging:
-+/- MRI of brain
-PET-CT with contrast of abdomen and pelvis
-Radionuclide bone scan
-PFTs
-Quantitative radionuclide V/Q lung scan- good for people with bad lung disease and youre nervous about surgery -> measures how much the lobe your removing is involving in V/Q
-Exercise testing

40
Q

staging NSCLC

A

-Stages are 1-4; with 4 being the worst
-Stage is determined by looking at 3 separate components
-T= Tumor size
-N= Lymph node involvement
-M= Absence or presence of metastasis
-recently anything stage 1a or more should get adjuvant chemo (bc resection isnt enough!)
-small cell- straight to chemo

41
Q

new tx for NSCLC: immunotherapy

A

-the use of medicines to help the immune system to recognize and destroy cancer cells more effectively
-target PD-1 or PDL-1 -> a protein on certain immune cells (calledT cells) that normally helps keep these cells from attacking other cells in the body
-By blocking PD-1, these drugs boost the immune response against cancer cells -> attack tumor cells!
-can shrink some tumors or slow their growth
-T cells identify the tumor as foreign

42
Q

immunotherapies: PD-1 and PDL-1

A

Target PD-1
-Nivolumab (Opdivo)
-Pembrolizumab (Keytruda)

Target PDL-1
-Mezolizumab (Tecentriq)
-Durvalumab (Imfinzi)

43
Q

mutations associated with NSCLC

A

-they are identifying different mutations of NSCLC and are able to create targeted immunotherapy
-if you have a target you can do this therapy -> almost like a chronic ds
-EGFR- best!

44
Q

non-small cell lung cancer SEER stage

A

-localized- 61% 5 year survival rate
-regional- 35%
-distant- 6%
-all SEER stages combined- 24$

45
Q

NSCLC survival

A

-68% survival even with resection -> thats why they recomend adjunctive chemo with it :(

46
Q

staging of SCLC

A

-Limited disease is defined as disease confined to the ipsilateral hemithorax and within a single radiotherapy port
-Extensive disease is defined as evident metastatic disease outside the ipsilateral hemithorax
-not TNM

47
Q

tx of SCLC

A

-disseminated in almost all pts
-Limited stage disease:
-Combination of chemotherapy and radiation therapy
-Surgery is not used except in the rare pt with a solitary pulmonary nodule without metastases or regional +LNs
-rare to find it easy and be able to do surgery

-Extensive stage SCLC:
-systemic Chemotherapy alone is initial therapy
-If responds to initial therapy radiation added
-with SCLC chemo and radiation can show cancer is gone -> and then it comes back -> false hope

48
Q

SCLC survival following chemo

A

-limited- 12-15% mean 5 year survival
-extensive- 2%

49
Q

metastatic lung cancer

A

-Spread to the lungs through vascular or lymphatic channels or by direct extension
-Almost any cancer can
-Metastases usually via the pulmonary artery
-Typically present as multiple* nodules or masses on chest radiography
-Metastases to lungs are found in 20–55% of patients dying of various malignancies:
-Most are intraparenchymal
-Endobronchial metastases <5% of pts

-Carcinoma of the kidney, breast, colon, and cervix and malignant melanoma are the most likely primary tumors!!

50
Q

differential dx of multiple pulmonary nodules includes

A

-Pulmonary arteriovenous malformation
-Pulmonary abscesses
-Granulomatous infection
-Sarcoidosis
-Rheumatoid nodules
-Wegener’s granulomatosis

51
Q

metastatic lung cancer symptoms

A

-Symptoms are uncommon:
-Cough, hemoptysis
-Dyspnea and hypoxemia (advanced)
-Symptoms are more often referable to the site of the primary tumor

52
Q

metastatic lung cancer imaging

A

-Chest radiographs usually show multiple spherical densities with sharp margins:
-More common in lower lung zones
-CT is more sensitive
-cannon ball neoplasm

53
Q

metastatic lung cancer dx

A

-Usually established by identifying a primary tumor
-If the history and physical examination fail to reveal the site of the primary tumor:
-Lung tissue samples obtained by bronchoscopy, percutaneous needle biopsy, or thoracotomy

54
Q

metastatic lung cancer tx

A

-tx of the primary neoplasm and any pulmonary complications

-Surgical resection of SOLITARY pulmonary nodule if:
-Primary tumor is under control
-Patient is a good surgical risk
-All of the metastatic tumor can be resected
-No metastases elsewhere in the body

-There are some contraindications to surgery -> Melanoma, pleural involvement, >1 met

55
Q

metastatic lung cancer prognosis

A

The overall 5-year survival rate in secondary lung cancer treated surgically is 20–35%

56
Q

lung cancer

A

-2nd MC malignancy in men and women, but number one cause of cancer death
-Lung cancer screening-Fleischner Society Guidelines*
-Small cell vs. Non small cell (potentially curable)
-Treatment is based on staging
-Surgery is tx of choice in early stage NSCLC
-Emerging treatment options for NSCLC -> Immunotherapy and targeted therapies